Replies to post #197247 on Biotech Values

[justrpaul]

Treatment naive and non-cirrhotic are the easiest and with only 91% SVR for GT1, why would they even advance to further testing?

[DewDiligence]

Today's ABBV/ENTA-vs-MRK data not apples-to-apples:

In the data reported today, all of MRK’s patients were treatment-naïve, while 10% of the ABBV/ENTA's patients in the highest-dose GT3 cohort were treatment-experienced.